Weight Watchers' decision to move into the new business area of facilitating access to obesity drugs could represent a commercial boon to manufacturers of the drugs like Novo Nordisk A/S and Eli Lilly and Company. Weight Watchers – with a subscriber base of 3.5 million individuals and a nearly 60-year heritage in weight management – is in a unique position to provide guidance to patients about how and when to use drug interventions to manage weight.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?